Mark Shepanski and Jeff Clement of PCI Pharma Services discuss their company’s investment in innovative robotic sterile fill-finish technologies, driving speed to the clinic for both early- and late-phase clinical trials, as well as commercial supply, while also providing an elevated degree of sterility assurance.
.svg)
